| Title |
Nivolumab-induced tumour-like gastritis: A case report / |
| Authors |
Čijauskaitė, Elena ; Kazėnaitė, Edita ; Strainienė, Sandra ; Sadauskaitė, Goda ; Kurlinkus, Benediktas |
| DOI |
10.12998/wjcc.v11.i18.4350 |
| Full Text |
|
| Is Part of |
World journal of clinical cases.. Pleasanton, CA : Baishideng Publishing Group Inc.. 2023, vol. 11, iss. 18, p. 4350-4359.. eISSN 2307-8960 |
| Keywords [eng] |
Nivolumab ; Immune checkpoint inhibitors ; Tumour-like gastritis ; Proton pump inhibitors ; Case report |
| Abstract [eng] |
BACKGROUND Immune checkpoint inhibitors are one of the modern treatment methods for advanced malignancies. However, this group of medications is also associated with various immune-related adverse events, such as colitis or pneumonitis. Immune checkpoint inhibitor-induced gastritis is a less common adverse event. CASE SUMMARY We describe a 64-year-old woman presenting with diarrhea, nausea, and discomfort in the upper abdominal region. The patient had a history of metastatic lung cancer, which was treated with nivolumab. During the first endoscopy, an infiltrating gastric tumour was suspected. Later, based on endoscopic, histological and radiological findings, nivolumab-induced gastritis was diagnosed. The patient was successfully treated with three courses of omeprazole. CONCLUSION As a consequence of the increased use of immune checkpoint inhibitors, a growing number of reported immune-related adverse events could be expected. The diagnosis of immune checkpoint inhibitor-induced gastritis should be considered when assessing a patient treated with nivolumab with upper gastrointestinal distress. |
| Published |
Pleasanton, CA : Baishideng Publishing Group Inc |
| Type |
Journal article |
| Language |
English |
| Publication date |
2023 |
| CC license |
|
